Evaluation of Circulating and Archived HIV-1 Integrase Drug-Resistance Variants among Patients on Third-Line ART in Cameroon: Implications for Dolutegravir-Containing Regimens in Resource-Limited Settings-Reference-Cited by-同舟云学术

Evaluation of Circulating and Archived HIV-1 Integrase Drug-Resistance Variants among Patients on Third-Line ART in Cameroon: Implications for Dolutegravir-Containing Regimens in Resource-Limited Settings

Published:2022-12-21 Issue:6 Volume:10 Page:
ISSN:2165-0497
Container-title:Microbiology Spectrum
language:en
Short-container-title:Microbiol Spectr

Author:

Fokam Joseph¹²³⁴,Ngoufack Jagni Semengue Ezechiel¹⁵⁶,Molimbou Evariste¹⁶,Etame Naomi-Karell¹⁷,Santoro Maria Mercedes⁵,Takou Désiré¹,Mossiang Leonella⁸,Meledie Alain Patrice⁹,Chenwi Collins Ambe¹¹⁰,Yagai Bouba¹⁵,Nka Alex Durand¹⁵⁶,Dambaya Beatrice¹,Teto Georges¹,Ka’e Aude Christelle¹¹¹,Beloumou Grâce Angong¹,Ndjeyep Sandrine Claire Djupsa¹,Fainguem Nadine¹⁵,Abba Aissatou¹,Kengni Aurelie Minelle Ngueko¹⁷,Tchouaket Michel Carlos Tommo¹⁷,Bouba Nounouce Pamen³¹²,Billong Serge-Clotaire³⁴¹³,Djubgang Rina¹⁴,Saounde Edith Temgoua¹³,Sosso Samuel Martin¹,Kouanfack Charles⁸¹⁵,Bissek Anne-Cecile Zoung-Kanyi³⁴¹⁶,Eben-Moussi Emmanuel¹,Colizzi Vittorio¹⁵⁶,Perno Carlo-Federico¹¹⁷^ORCID,Ceccherini-Silberstein Francesca⁵^ORCID,Ndjolo Alexis¹³

Affiliation:

1. Chantal BIYA International Reference Centre for Research on HIV/AIDS Management and Care, Yaoundé, Cameroun

2. Faculty of Health Sciences, University of Buea, Buea, Cameroon

3. Faculty of Medicine and Biomedical Sciences, University of Yaoundé I, Yaoundé, Cameroun

4. National HIV Drug Resistance Working Group, Ministry of Public Health, Yaoundé, Cameroun

5. University of Rome Tor Vergata, Rome, Italy

6. Evangelical University of Cameroon, Bandjoun, Cameroon

7. School of Health Sciences, Catholic University of Central Africa, Yaoundé, Cameroun

8. Yaoundé Central Hospital, Yaoundé, Cameroun

9. Douala General Hospital, Douala, Cameroon

10. Mvangan District Hospital, Mvangan, Cameroon

11. PhD Courses in Microbiology, Immunology, Infectious Diseases and Transplants (MIMIT), University of Rome “Tor Vergata”, Rome, Italy

12. Directorate for Disease, Epidemic and Pandemic Control, Yaounde, Cameroon

13. Central Technical Group, National AIDS Control Committee, Yaoundé, Cameroun

14. Directorate of Pharmacy, Drug and Laboratory, Ministry of Public Health, Yaoundé, Cameroun

15. Faculty of Medicine and Pharmaceutical Sciences, University de Dschang, Dschang, Cameroon

16. Division of Operational Health Research, Ministry of Public Health, Yaoundé, Cameroun

17. Bambino Gesu Pediatric Hospital, Rome, Italy

Abstract

We described the analysis of the genotypes of the population within third-line antiviral therapy in Cameroon, with a focus on defining the effects of prior raltegravir (RAL) treatment and resistance mutations for current dolutegravir (DTG) treatment. While supporting the current transition to DTG-containing ART in resource-limited settings toward the achievement of the UNAIDS’ goal of HIV elimination by 2030, our findings suggested that RAL-exposed patients may need a specific monitoring approach either in a stratified or personalized model of third-line ART to ensure the long-term success of DTG-containing regimens.

Funder

Royal Society of Tropical Medicine and Hygiene

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Cell Biology,Microbiology (medical),Genetics,General Immunology and Microbiology,Ecology,Physiology

Link

https://journals.asm.org/doi/pdf/10.1128/spectrum.03420-22

Reference70 articles.

1. WHO. 2013. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. doi:10.1097/00022744-199706000-00003.

2. WHO. 2016. Global report on early warning indicators of HIV drug resistance. doi:10.1016/j.quaint.2018.06.014.

3. The Role of Human Immunodeficiency Virus (HIV) Asymptomatic Status When Starting Antiretroviral Therapy on Adherence and Treatment Outcomes and Implications for Test and Treat: The Swiss HIV Cohort Study

4. Détection de mutations de résistance du VIH aux antirétroviraux : vers un dépistage rapide pré-thérapeutique ?

5. Week 96 Genotypic and Phenotypic Results of the Fostemsavir Phase 3 BRIGHTE Study in Heavily Treatment-Experienced Adults Living with Multidrug-Resistant HIV-1

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting the gut–microbiota–brain axis in irritable bowel disease to improve cognitive function – recent knowledge and emerging therapeutic opportunities;Reviews in the Neurosciences;2023-02-10